A recent study highlights the 'bird's nest sign' as a novel initial presentation of primary pulmonary B-cell non-Hodgkin lymphoma with plasmacytic differentiation. This finding may enhance diagnostic accuracy for this rare lymphoma subtype.

AbbVie and Genmab's dual-acting drug, Epkinly, shows promising results in a frontline trial for newly diagnosed diffuse large B-cell lymphoma (DLBCL). Analysts suggest it could become the new standard of care for this patient population.

AbbVie and Genmab's bispecific antibody, Epkinly, demonstrated a 51% improvement in progression-free survival in a Phase 3 trial for diffuse large B cell lymphoma, potentially establishing a new standard of care. This significant result positions Epkinly to compete with Roche's Polivy in the frontline treatment landscape.

A recent study analyzes prognostic factors and survival rates in HHV8 positive diffuse large B cell lymphoma using national cancer database data. The findings may inform treatment strategies and patient management for this rare lymphoma subtype.

A recent study highlights hemophagocytic lymphohistiocytosis as a potential initial presentation of occult diffuse large B-cell lymphoma, posing significant diagnostic challenges. This finding underscores the need for heightened awareness among clinicians to improve early detection and treatment outcomes.